JNJ-26990990

JNJ-26990990 is a broad-spectrum anticonvulsant drug currently under development by Janssen Pharmaceutica as a second-generation follow-up to the marketed drug topiramate.[1][2] It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic anhydrase inhibition.[1] It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression.[3]

JNJ-26990990
Clinical data
Other namesN-((Benzo[b]thien-3-yl)methyl)sulfamide
Identifiers
IUPAC name
  • 3-[(Sulfamoylamino)methyl]-1-benzothiophene
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC9H10N2O2S2
Molar mass242.31 g·mol−1
 NY (what is this?)  (verify)

JNJ-26990990 entered phase II clinical trials in October 2007.[4]

Metabolites and radioactive isotope-labeled derivatives of JNJ-26990990 have also been prepared to support its development.[5]

See also

References
  1. Parker MH, Smith-Swintosky VL, McComsey DF, Huang Y, Brenneman D, Klein B, et al. (December 2009). "Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies". Journal of Medicinal Chemistry. 52 (23): 7528–36. doi:10.1021/jm801432r. PMID 19388676.
  2. WO patent 2006023861, Parker MH, Reitz AB, Maryanoff BE, "Preparation of benzo-fused heteroaryl sulfamide derivatives for the treatment of epilepsy and related disorders", issued 2006-03-02, assigned to Janssen Pharmaceutica
  3. "JNJ 26990990 Johnson & Johnson developing anticonvulsant Johnson & Johnson preclinical data". R & D Focus Drug News. September 22, 2008. Archived from the original on October 12, 2012.
  4. Fischer J, Ganellin CR (2010). "Chapter 2. Standalone Drugs". Analogue-Based Drug Discovery II. doi:10.1002/9783527630035.ch2.
  5. Lin R, Weaner LE, Hoerr DC, Salter R, Gong Y (January 2013). "Expeditious syntheses of stable and radioactive isotope-labeled anticonvulsant agent, JNJ-26990990, and its metabolites". Journal of Labelled Compounds & Radiopharmaceuticals. 56 (1): 22–6. doi:10.1002/jlcr.3013. PMID 24285137.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.